Brokerages Set MaxCyte, Inc. (NASDAQ:MXCT) PT at $5.50

Shares of MaxCyte, Inc. (NASDAQ:MXCT) have been given a consensus rating of “Hold” by the five analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $5.50.

A number of brokerages have recently commented on MXCT. Weiss Ratings reissued a “sell (e+)” rating on shares of MaxCyte in a research report on Friday, April 24th. Craig Hallum decreased their price objective on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th. Finally, Wall Street Zen raised shares of MaxCyte from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th.

Institutional Trading of MaxCyte

A number of institutional investors have recently bought and sold shares of MXCT. Capricorn Fund Managers Ltd bought a new stake in MaxCyte in the 1st quarter valued at about $5,760,000. Brooklands Fund Management Ltd acquired a new position in shares of MaxCyte in the 1st quarter valued at approximately $1,538,000. Kennedy Capital Management LLC acquired a new position in shares of MaxCyte in the 3rd quarter valued at approximately $3,330,000. Mirabella Financial Services LLP raised its position in shares of MaxCyte by 24.2% in the 3rd quarter. Mirabella Financial Services LLP now owns 8,200,000 shares of the company’s stock valued at $12,956,000 after buying an additional 1,600,000 shares in the last quarter. Finally, AXA S.A. raised its position in shares of MaxCyte by 123.2% in the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock valued at $4,801,000 after buying an additional 1,215,481 shares in the last quarter. Institutional investors own 68.81% of the company’s stock.

MaxCyte Stock Performance

MXCT opened at $1.12 on Wednesday. MaxCyte has a twelve month low of $0.64 and a twelve month high of $2.37. The firm’s fifty day moving average is $0.96 and its two-hundred day moving average is $1.07. The firm has a market cap of $119.97 million, a PE ratio of -3.03 and a beta of 1.48.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.06. The firm had revenue of $6.22 million during the quarter, compared to the consensus estimate of $7.28 million. MaxCyte had a negative return on equity of 20.03% and a negative net margin of 121.16%. Equities analysts forecast that MaxCyte will post -0.3 EPS for the current fiscal year.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.